GPhA: AbbVie's Petition On US Biosimilars A Ploy To Delay Interchangeables
This article was originally published in SRA
Executive Summary
AbbVie Inc's citizen petition calling for a public hearing1 before the US Food and Drug Administration issues its long-awaited biosimilars guidance on interchangebility is nothing more than a "thinly disguised" ploy to block cheaper biologics that may be substituted for the brand-name products, the Generic Pharmaceutical Association (GPhA) and its affiliated Biosimilars Council argued in public comments submitted to the US regulatory agency.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.